Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
19 July 2019 | Story Eloise Calitz | Photo Charl Devenish
Human Rights ambassadors programme
Mihle Tyatyaza and Musa Makupu are two of the human rights ambassadors.
Gernus Terblanche is a PHD student in Virology; he is currently the prime of the Imperium city residence and a proud human-rights ambassador. What he values most about this role, is the opportunity to have open and honest conversations about human-rights issues.

Students in residences are often confronted with human-rights issues; this initiative has created a platform for open dialogue on critical issues that did not exist in the past. Ambassadors play a critical role in ensuring that the rights of resident students are not infringed. “I have learned a lot about the planning of events and leadership, and my knowledge of human rights has increased significantly,” says Terblanche.

The programme

The Human Rights Ambassadors programme was launched in 2016 under the Advocacy division of the Free State Centre for Human Rights. The main objectives of the programme are to establish and strengthen a culture of human rights within all the UFS residences. This is based on the belief that the dignity of all must be respected and protected, as stated in the South African Constitution. The long-term objective is to expand the service to the Qwaqwa Campus and to include and serve communities surrounding all three UFS campuses.

How do you become an ambassador?
 
Each residence appoints a human-rights ambassador. The ambassador has to ensure that the values and practices of the residence respects the human rights of all. Ambassadors are required to undertake awareness-raising activities to achieve these goals. Mihle Tyatyaza and Mosa Makupu are two of the ambassadors who benefit from this programme. 

Tyatyaza, a BA Social Science undergraduate and the human-rights representative for House Veritas, says the exposure he gained though engagement with other students on this platform will assist him with his studies and future career. He is excited about the fact that students now have the opportunity to share their experiences and thereby learn more about human rights. 

Makupu, a BSc Mathematical Statistics undergraduate and the human rights representative for House Madelief, believes that she has gained a better understanding of the importance of human rights through this programme, as well as the lack of knowledge most students have. This has guided her to educate other students. What she experienced, is that some students do not even realise that their basic rights are violated; now she can make a difference through education and regular engagements with resident students. 

Scope of awareness activities

Activities include dialogue sessions, seminars, and theatrical productions. These activities are grouped within various themes, including sexual harassment, gender-based violence, LGBTIQ rights, and the right to academic privacy. The 2019 theme for awareness-raising activities is Dignity. 

Importance of collaboration

The programme functions in close collaboration with the provincial offices of the South African Human Rights Commission, the Commission for Gender Equality, and the UFS Office of Gender and Sexual Equity. Together with the Residence Committees and the Values and Strategies Committees of each residence, the ambassadors strive to uphold the values of respect and inclusion in the residence.

Annelie de Man, Coordinator: Advocacy Division in the Free State Centre for Human Rights, says the benefits of the programme are evident in the progress that has been made in terms of creating awareness among resident students. What also sparked this awareness, was the successful implementation of various activities by the ambassadors, especially on 21 March – Human Rights Day. The programme is closely managed, and each ambassador submits bi-annual reports to track trends, activities, and learnings. One of the commendable achievements this year was the collaboration between the ambassadors and the residence committees that supported the drive for equality and non-discrimination.  

Upcoming initiatives

Date: 23 July 2019 
Venue: Albert Wessels Auditorium
Theme: The freedom of expression showcase

The programme is coordinated by the ambassadors of House NJ van der Merwe, House Villa Bravado, and House Welwitschia. This event will provide students with a platform to socialise and discuss issues around human rights.

Date: 23 August 2019
Theme: Cultural showcase ‘Now we are Free’.  

Ambassadors from all the residences on campus are hosting a culture showcase. The focus of this event is based on our 2019 theme, ‘Dignity’ and freedom of expression. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept